Skip to main content
Premium Trial:

Request an Annual Quote

New York State Clears Sequenom's Prenatal RhD-Incompatibility Dx

NEW YORK (GenomeWeb News) — Sequenom today said that New York State health officials have approved a noninvasive prenatal test based on the firm’s SEQureDx technology for cell-free fetal nucleic-acid assessment.
The lab-developed test, performed on a real-time PCR platform, is designed to detect Rhesus D incompatibility. It will be marketed by Lenetix Medical Screening Laboratory, Sequenom’s CLIA-certified, nonexclusive licensee.
Sequenom’s SEQureDx technology determines the genetic status of the fetus by extracting fetal nucleic-acid material from a maternal blood specimen. The test for RhD incompatibility could avoid maternal alloimmunization and resulting hemolytic disease in the newborn, Sequenom said.
Alloimmunization most frequently occurs when an RhD-negative mother is exposed to red blood cells of an RhD-positive fetus, which produced maternal antibodies against the RhD antigen.
“Although the pregnancy in which alloimmunization first occurs results in an unaffected child, future children are at substantial risk of anemia and in the worst cases, fetal death,” the company added.
In the US RhD incompatibility occurs in more than 10 percent of all pregnancies, according to Sequenom.
The approval, the first based on the SEQureDx technology, “represents a significant step in our strategy to build a proprietary global portfolio of noninvasive prenatal products,” Sequenom CEO Harry Stylli said in a statement. The test “will serve in assisting in preparing us in developing and launching other tests,” including screens for FetalXY and Down syndrome.
“Genetic-based noninvasive prenatal testing could complement and potentially present a paradigm shift from current invasive testing procedures such as amniocentesis,” said Stylli. “Tests based on our SEQureDx technology can be performed from a simple maternal blood sample, which could allow obstetric and fetal maternal specialists to successfully intervene early in the pregnancy to improve outcomes.”

The Company expects to start introducing additional noninvasive prenatal tests in the first half of 2008.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.